LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Khan, Sabiya Samim"
  2. AU="Caldwell, Maeve"
  3. AU=Yan Nao
  4. AU="Hiva Kabgani"
  5. AU="Toporcerová, Silva"
  6. AU="Felici, Angelina"
  7. AU="Bai, Bingyao"
  8. AU="Woodhead, Jon D"
  9. AU="Wojnarowicz, Mark W"
  10. AU="Cox, Rebecca Jane"
  11. AU="Huang, Bijun"
  12. AU="Marriage, Keith"
  13. AU=Ren Ziyuan
  14. AU="Tae-Houn Kim"
  15. AU="Mias-Lucquin, Dominique"
  16. AU="Karagiannidis, Artemios G"
  17. AU="Alice H Reis"
  18. AU="Malik, Shahbaz A"
  19. AU=Mittal Rajat AU=Mittal Rajat
  20. AU="Seguin, Rebecca A"
  21. AU="Tinbergen, Jan"
  22. AU="Rodrigues-Díez, Raquel"
  23. AU="Yang, Haihao"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update.

    Khan, Sabiya Samim / Khatik, Gopal L / Datusalia, Ashok K

    Current neuropharmacology

    2022  Band 21, Heft 2, Seite(n) 309–339

    Abstract: Memory, cognition, dementia, and neurodegeneration are complexly interlinked processes with various mechanistic pathways, leading to a range of clinical outcomes. They are strongly associated with pathological conditions like Alzheimer's disease, ... ...

    Abstract Memory, cognition, dementia, and neurodegeneration are complexly interlinked processes with various mechanistic pathways, leading to a range of clinical outcomes. They are strongly associated with pathological conditions like Alzheimer's disease, Parkinson's disease, schizophrenia, and stroke and are a growing concern for their timely diagnosis and management. Several cognitionenhancing interventions for management include non-pharmacological interventions like diet, exercise, and physical activity, while pharmacological interventions include medicinal agents, herbal agents, and nutritional supplements. This review critically analyzed and discussed the currently available agents under different drug development phases designed to target the molecular targets, including cholinergic receptor, glutamatergic system, GABAergic targets, glycine site, serotonergic targets, histamine receptors, etc. Understanding memory formation and pathways involved therein aids in opening the new gateways to treating cognitive disorders. However, clinical studies suggest that there is still a dearth of knowledge about the pathological mechanism involved in neurological conditions, making the dropouts of agents from the initial phases of the clinical trial. Hence, a better understanding of the disease biology, mode of drug action, and interlinked mechanistic pathways at a molecular level is required.
    Mesh-Begriff(e) Humans ; Alzheimer Disease/complications ; Alzheimer Disease/drug therapy ; Parkinson Disease/metabolism ; Cognition Disorders ; Receptors, Cholinergic ; Cognition
    Chemische Substanzen Receptors, Cholinergic
    Sprache Englisch
    Erscheinungsdatum 2022-04-11
    Erscheinungsland United Arab Emirates
    Dokumenttyp Review ; Journal Article
    ZDB-ID 2192352-8
    ISSN 1875-6190 ; 1570-159X
    ISSN (online) 1875-6190
    ISSN 1570-159X
    DOI 10.2174/1570159X20666220411083922
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6150: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Phytochemicals in the Management of Arsenic Toxicity.

    Khan, Sabiya Samim / Sharma, Ankita / Flora, Swaran J S

    Chemical research in toxicology

    2022  Band 35, Heft 6, Seite(n) 916–934

    Abstract: Arsenic toxicity is a major concern due to its deleterious consequences for human health. Rapid industrialization also has weakened the quality of the environment by introducing pollutants that may disrupt balanced ecosystems, adversely and irreversibly ... ...

    Abstract Arsenic toxicity is a major concern due to its deleterious consequences for human health. Rapid industrialization also has weakened the quality of the environment by introducing pollutants that may disrupt balanced ecosystems, adversely and irreversibly impacting humans, plants, and animals. Arsenic, an important toxicant among all environmental hazards, can lead to several detrimental effects on cells and organs, impacting the overall quality of life. Nevertheless, arsenic also has a rich history as a chemotherapeutic agent used in ancient days for the treatment of diseases such as malaria, cancer, plague, and syphilis when other chemotherapeutic agents were yet to be discovered. Arsenicosis-mediated disorders remain a serious problem due to the lack of effective therapeutic options. Initially, chelation therapy was used to metabolically eliminate arsenic by forming a complex, but adverse effects limited their pharmacological use. More recently, plant-based products have been found to provide significant relief from the toxic effects of arsenic poisoning. They act by different mechanisms affecting various cellular processes. Phytoconstituents such as curcumin, quercetin, diallyl trisulfide, thymoquinone, and others act via various molecular pathways, primarily by attenuating oxidative damage, membrane damage, DNA damage, and proteinopathies. Nonetheless, most of the phytochemicals reviewed here protect against the adverse effects of metal or metalloid exposure, supporting their consideration as alternatives to chelation therapy. These agents, if used prophylactically and in conjunction with other chemotherapeutic agents, may provide an effective approach for management of arsenic toxicity. In a few instances, such strategies like coadministration of phytochemicals with a known chelating agent have led to more pronounced elimination of arsenic from the body with lesser off-site adverse effects. This is possible because combination treatment ensures the use of a reduced dose of chelating agent with a phytochemical without compromising treatment. Thus, these therapies are more practical than conventional therapeutic agents in ameliorating arsenic-mediated toxicity. This review summarizes the potential of phytochemicals in alleviating arsenic toxicity on the basis of available experimental and clinical evidence.
    Mesh-Begriff(e) Animals ; Arsenic/metabolism ; Arsenic/toxicity ; Arsenic Poisoning/drug therapy ; Arsenic Poisoning/metabolism ; Chelating Agents ; Ecosystem ; Phytochemicals/pharmacology ; Phytochemicals/therapeutic use ; Quality of Life
    Chemische Substanzen Chelating Agents ; Phytochemicals ; Arsenic (N712M78A8G)
    Sprache Englisch
    Erscheinungsdatum 2022-05-16
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 639353-6
    ISSN 1520-5010 ; 0893-228X
    ISSN (online) 1520-5010
    ISSN 0893-228X
    DOI 10.1021/acs.chemrestox.2c00023
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2320: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay.

    Naren, Padmashri / Cholkar, Anjali / Kamble, Suchita / Khan, Sabiya Samim / Srivastava, Saurabh / Madan, Jitender / Mehra, Neelesh / Tiwari, Vinod / Singh, Shashi Bala / Khatri, Dharmendra Kumar

    Journal of Alzheimer's disease : JAD

    2022  Band 94, Heft s1, Seite(n) S399–S428

    Abstract: Parkinson's disease (PD) is the second most common neurodegenerative illness majorly affecting the population between the ages of 55 to 65 years. Progressive dopaminergic neuronal loss and the collective assemblage of misfolded alpha-synuclein in the ... ...

    Abstract Parkinson's disease (PD) is the second most common neurodegenerative illness majorly affecting the population between the ages of 55 to 65 years. Progressive dopaminergic neuronal loss and the collective assemblage of misfolded alpha-synuclein in the substantia nigra, remain notable neuro-pathological hallmarks of the disease. Multitudes of mechanistic pathways have been proposed in attempts to unravel the pathogenesis of PD but still, it remains elusive. The convergence of PD pathology is found in organelle dysfunction where mitochondria remain a major contributor. Mitochondrial processes like bioenergetics, mitochondrial dynamics, and mitophagy are under strict regulation by the mitochondrial genome and nuclear genome. These processes aggravate neurodegenerative activities upon alteration through neuroinflammation, oxidative damage, apoptosis, and proteostatic stress. Therefore, the mitochondria have grabbed a central position in the patho-mechanistic exploration of neurodegenerative diseases like PD. The management of PD remains a challenge to physicians to date, due to the variable therapeutic response of patients and the limitation of conventional chemical agents which only offer symptomatic relief with minimal to no disease-modifying effect. This review describes the patho-mechanistic pathways involved in PD not only limited to protein dyshomeostasis and oxidative stress, but explicit attention has been drawn to exploring mechanisms like organelle dysfunction, primarily mitochondria and mitochondrial genome influence, while delineating the newer exploratory targets such as GBA1, GLP, LRRK2, and miRNAs and therapeutic agents targeting them.
    Mesh-Begriff(e) Humans ; Aged ; Parkinson Disease/therapy ; Parkinson Disease/drug therapy ; alpha-Synuclein/metabolism ; Mitochondria/metabolism ; Oxidative Stress/physiology
    Chemische Substanzen alpha-Synuclein
    Sprache Englisch
    Erscheinungsdatum 2022-09-10
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Review
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-220682
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6084: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang